Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Crossref DOI link: https://doi.org/10.1007/s40744-018-0097-3
Published Online: 2018-02-22
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cohen, Stanley
Curtis, Jeffrey R.
DeMasi, Ryan
Chen, Yan
Fan, Haiyun
Soonasra, Arif
Fleischmann, Roy
Funding for this research was provided by:
Pfizer Inc
Text and Data Mining valid from 2018-02-22
Article History
Received: 13 November 2017
First Online: 22 February 2018